PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.20
Ask: 8.30
Change: -0.34 (-3.95%)
Spread: 0.10 (1.22%)
Open: 8.50
High: 8.50
Low: 8.26
Prev. Close: 8.60
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investee Company Update: Liberation Labs

12 Apr 2023 12:00

RNS Number : 9964V
Agronomics Limited
12 April 2023
 

12.00pm 12th April 2023

Agronomics Limited

 ("Agronomics" or the "Company")

Liberation Labs Secures $30 Million in Equipment Funding for First Biomanufacturing Facility

Agronomics (ANIC:LSE), the leading listed company focused on the field of cellular agriculture, is pleased to announce that Liberation Labs Holdings Inc ("Liberation Labs"), the large-scale precision fermentation contract manufacturer, has secured $30 million in equipment funding for the first dedicated, purpose-built, commercial precision fermentation plant globally for food production.

The Company has invested a total of US $7.63 million since Liberation Labs' inception, which is currently carried at US $25.4m, with this accounting for approximately 11.4% of the last published Net Asset Value of Agronomics (31.12.22). Agronomics has an equity ownership of 37.4% on a fully diluted basis in Liberation Labs.

The full announcement is set out below without any material changes:

Funding advances project development for a new facility that will be the first purpose-built commercial precision fermentation plant in the United States.

RICHMOND, Ind. (Embargo until April 12, 2023) Liberation Labs, industrial biotech's fabrication partner, has secured $30 million in equipment financing to advance development of its first commercial-scale biomanufacturing facility in Richmond, Indiana. The new facility will have a fermentation capacity of 600,000 liters with a fully dedicated downstream process (DSP). Ground breaking is expected in June 2023 with initial plant startup by the end of 2024.

Liberation Labs is focused on enabling the commercial availability of bioproducts that will meet the growing demand from existing major CPG and ingredient brands as well as from the emerging crop of precision fermentation-focused startups. The new facility will be the first purpose-built commercial-scale precision fermentation plant in the United States. The company has commenced the detailed design engineering phase and has placed orders for all of the major engineered equipment, including its 150,000 litre fermenters and DSP separation and drying units, all while continuing to build out the engineering and operations teams.

"This new financing, combined with our seed raise, allows us to not only secure all the needed equipment, but also to continue investing in our team to move the overall project forward at speed,"

said Mark Warner, co-founder and CEO of Liberation Labs. "Traditionally it is challenging to secure this kind of financing for a first-of-a-kind facility, but this lease reflects the belief in our vision and strong team by our committed equity and equipment finance investors."

The facility comes at a time of increasing focus on both the importance of a domestic biorefining industry, and the current lack of major projects. In September 2022, President Biden launched a National Biotechnology and Biomanufacturing Initiative designed to stimulate development and create domestic jobs, build stronger supply chains, lower costs for Americans. The new facility, the first in the US fully dedicated to novel bioproducts, could catalyze market demand, commercializing innovation among food, chemical and materials biotechnology companies and their associated economic, health and environmental benefits.

About Liberation Labs

Liberation Labs is commercialising precision fermentation with a global network of purpose-built, international manufacturing facilities that enable the next wave of biotechnology advancements to produce bio-based consumer products at scale. We combine modern technology with fit-for-purpose design to bring reliable and cost-effective solutions that meet customer demand across the world. More information is available at www.liberationlabs.com.

Media Contact

John Williams, Scoville PR for Liberation Labs

+1-206-660-5503, jwilliams@scovillepr.com

About Agronomics

Agronomics is a leading listed alternative proteins company with a focus on cellular agriculture and cultivated meat. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to secure minority stakes in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and be fundamental to feeding the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

 

About Cellular Agriculture

Cellular Agriculture is the production of agriculture products directly from cells, as opposed to raising an animal for slaughter or growing crops. This encompasses cell culture to produce cultivated meat and materials, and fermentation processes that harness a combination of molecular biology, synthetic biology, tissue engineering and biotechnology to massively simplify production methods in a sustainable manner.

 

Over the coming decades, the source of the world's food supply traditionally derived from conventional agriculture is going to change dramatically. We have already witnessed the first wave of this shift with the consumer adoption of plant-based alternative proteins but today, we are on the cusp of an even bigger wave of change. This is being facilitated by advances in cellular agriculture. This change is necessary, given scientists' claims that if we maintain existing animal protein consumption patterns, then we will not meet the Paris Agreement's goal of limiting warming to 1.5℃.

 

AT Kearney, a global consultancy firm, projects that cultivated meat's market share will reach 35% by 2040. This combined with the Good Food Institute's estimate that a US $1.8 trillion investment will be required in order to produce just 10% of the world's protein using this technology, means that we are on the cusp of a multi-decade flow of capital to build out manufacturing facilities. Funding in the field of cellular agriculture is accelerating, however, still less than US$ 5 billion has been invested worldwide since the industry's inception in 2016.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord

Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

 

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen

(Head of Equities)

Giles Balleny

Max Gould

Michael Johnson

Lucy Williams

Charles Goodfellow

 Ed Orlebar

Alistair Walker

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPUGACUPWGUP
Date   Source Headline
26th Sep 20228:48 amRNSEdison issues flash on Agronomics (ANIC)
21st Sep 20227:00 amRNSPortfolio Company Update: Onego Bio
21st Sep 20227:00 amRNSAgronomics Capital Markets Day 3rd November
8th Sep 20227:00 amRNSPortfolio Update: Bond Pet Foods Completes Funding
7th Sep 20227:00 amRNSPortfolio Company Onego Bio Awarded Grant Funding
11th Aug 20227:00 amRNSEdison issues update on Agronomics (ANIC)
4th Aug 20227:00 amRNSAgronomics Leads All G Foods Series A Financing
1st Aug 20227:00 amRNSAgronomics Leads Clean Food Group’s Seed Financing
25th Jul 20224:40 pmRNSSecond Price Monitoring Extn
25th Jul 20224:35 pmRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSNet Asset Value calculation to 30 June 2022
20th Jul 20229:03 amRNSPortfolio Company Update: Meatable
18th Jul 202212:24 pmRNSAgronomics July 2022 Newsletter
14th Jul 20227:00 amRNSAppointment of Joint Corporate Broker
8th Jul 202212:29 pmRNSInvestee Company Update: Tropic Biosciences
5th Jul 20227:00 amRNSExercise of Warrants and Total Voting Rights
20th Jun 20227:00 amRNSFinancing of Liberation Labs with CPT Capital
16th May 20229:52 amRNSHolding(s) in Company
6th May 20227:00 amRNSAgronomics Follow-on Investment in CellX
4th May 20229:00 amRNSPortfolio Company VitroLabs completes financing
25th Apr 20227:00 amRNSIssue of Performance Shares & Directors' Dealings
22nd Apr 20227:00 amRNSNet Asset Value calculation to 31st March 2022
5th Apr 20221:25 pmRNSExercise of Warrants, Total Voting Rights
23rd Mar 20229:30 amRNSAnnounces the Trading Facility of Warrants
21st Mar 20228:00 amRNSLaunch of Cultivated Meat Pet Food Venture
18th Mar 20227:00 amRNSANIC Joins the Alternative Proteins Association
14th Mar 20227:00 amRNSAgronomics Follow on Investment in GALY CO.
8th Mar 20227:00 amRNSAgronomics co-leads SuperMeat’s Series A Financing
24th Feb 20227:00 amRNSAgronomics welcomes Senior Investment Associate
22nd Feb 20227:00 amRNSAgronomics Leads Onego Bio's Seed Funding Round
21st Feb 20228:33 amRNSAgronomics Acquires Stake in Geltor, Inc
3rd Feb 20227:00 amRNSInterim Results
2nd Feb 202212:17 pmRNSResult of AGM
27th Jan 20228:00 amRNSPortfolio Company Update: BlueNalu
10th Jan 20228:12 amRNSExercise of Warrants
24th Dec 202111:51 amRNSHolding(s) in Company
23rd Dec 20211:11 pmRNSHolding(s) in Company
23rd Dec 202110:53 amRNSAgronomics December 2021 Newsletter
21st Dec 20212:29 pmRNSOpen Offer Results Subscription PDMR Dealing & TVR
16th Dec 20217:00 amRNSFinal Results and Notice of AGM
10th Dec 202111:08 amRNSHolding(s) in Company
8th Dec 20218:30 amRNSPortfolio Company Update: The EVERY Company
2nd Dec 20211:30 pmRNSResults of the Placing and Subscription
1st Dec 202111:30 amRNSProposed Fundraise to raise minimum £25 million
19th Nov 20217:00 amRNSAgronomics Leads Ohayo Valley’s Pre-Seed Funding
11th Nov 20217:00 amRNSPortfolio Company Update: Tropic Biosciences
5th Nov 20217:00 amRNSNet Asset Value calculation to 30 September 2021
4th Nov 20217:00 amRNSUS$ 8 million investment in The EVERY Company
3rd Nov 20217:00 amRNSAnnounces Launch of New Website
26th Oct 20217:00 amRNSAgronomics EUR3 million investment in Solar Foods

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.